Clear Search

Nadine M. Tung, MD

Beth Israel Deaconess Medical Center
Boston, Massachusetts

Titles and Affiliations

Director, Cancer Risk and Prevention Program
Beth Israel Deaconess Medical Center
Professor of Medicine, Harvard Medical School

Research area

Understanding the molecular nature of treatment response and resistance in breast cancer.


The BRCA1 and BRCA2 genes are the most affected genes in hereditary breast and ovarian cancers. Normally, BRCA1 and BRCA2 function to ensure the proper repair of DNA damage, but mutations in these genes lead to rapid accumulation of DNA errors, which leads to cancer. However, this defect also makes BRCA-mutated cells vulnerable to treatments that cause DNA damage. Cisplatin, a platinum-containing chemotherapy agent not typically used to treat breast cancer, has demonstrated good activity in BRCA mutation carriers with breast cancer and in some women with triple-negative breast cancer (TNBC). Recently, Drs. Tung and Schnitt completed the INFORM trial, which showed that while cisplatin is an active agent in BRCA mutation carriers with breast cancer, it was not more effective than the standard chemotherapy regimen. Drs. Tung and Schnitt are evaluating why some breast cancers respond to chemotherapy, including platinum chemotherapy, and other breast cancers do not.

Progress Thus Far

Drs. Tung and Schnitt are using artificial intelligence (AI) to analyze tumor tissue and blood collected as part of the INFORM trial to identify predictors of chemotherapy response. These samples represent the largest group of breast cancers from BRCA mutation carriers to undergo such an extensive molecular analysis. They found that nearly all the breast cancers had loss of the normal copy of the relevant BRCA gene in the tumor, that they had a pattern of gene abnormalities characteristic of breast cancers that develop in BRCA mutation carriers, and that they demonstrated an inability to repair DNA damage. Additionally, they identified a subset of estrogen receptor (ER)-positive breast cancers that closely resemble TNBC molecularly. Importantly, they found that tumors more responsive to chemotherapy had more immune cells infiltrating and were significantly enriched for genes related to immune activation. Tumors that had a higher rate of proliferation and had a higher immune profile were more responsive to chemotherapy.

What’s next

In the upcoming year, Drs. Tung and Schnitt will continue with their analysis of the tumor and blood samples using AI, state-of-the-art genetic sequencing techniques, and spatial transcriptomics (a method used to assign cell types to their locations in microscopic tissue sections). They plan to refine their prediction tools by including other markers of tumor proliferation and immune activation and adding patient clinical data, such as age at diagnosis, tumor size and lymph node involvement. The markers will be validated with other clinical trial databases, such as those comparing platinum and standard chemotherapy in patients with TNBC. Although this work is being conducted in breast cancers that developed in BRCA mutation carriers, the results will also help to understand the behavior of breast cancers in women without these inherited mutations.


Nadine Tung, MD is the Director of the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center (BIDMC), which she established in 1997 to evaluate patients and families with hereditary cancer syndromes. She is also a breast medical oncologist and a member of the Dana-Farber Harvard Cancer Center as well as Professor of Medicine at Harvard Medical School. She graduated from Princeton University in 1980 and Harvard Medical School in 1984. Dr. Tung’s research focuses on hereditary causes of breast cancer as well as effective strategies for breast cancer prevention and treatment. Much of her research has focused on women with BRCA1 and BRCA2 mutations, studying the genetic and environmental factors that influence cancer development as well as the biology and prognosis of the breast cancers they develop. Dr. Tung was recently elected as a Fellow of the American Society of Clinical Oncology (ASCO).

BCRF Investigator Since


Donor Recognition

The Joan Lunden Award


Stuart J. Schnitt, MD

Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center
Boston, Massachusetts